News

Opinion
The New Times on MSN1dOpinion
How Kigali is becoming Africa’s biopharma capital
Several recent developments point to Kigali’s growing role in Africa’s biopharmaceutical landscape. Rwanda has positioned itself as a strategic hub through a combination of investment in scientific ...
BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an all-stock deal valued at around $1.25 billion. Under the terms of the ...
See the latest BioNTech SE ADR stock price (BNTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
It has licensed a PD-L1xVEGF bispecific antibody developed by BioNTech for a massive $1.5 billion upfront, another $2 billion in "anniversary payments" through to 2027, and up to $7.6 billion in ...
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 GlobeNewswire Apr 24, 2025, 3:45:00 AM ...
Elev 758 ft, 50.81 °N, 8.77 °E Marburg, Hesse, Germany Weather Conditions star_ratehome ...